One of the forefront studies focuses on the unique population of adolescent and young adult (AYA) cancer survivors, individuals diagnosed between the ages of 18 and 39. This group has experienced rising cancer incidence rates over the past decade, yet their long-term health trajectories remain poorly understood. Led by oncologist and research scientist Alique Topalian, PhD, the investigation analyzes the baseline characteristics of AYA survivors receiving care in one of the nation’s few oncology primary care clinics specifically designed for cancer survivors. Utilizing a prospective clinical registry aimed at capturing longitudinal health outcomes, the team discovered that roughly 10% of the clinic’s patients were diagnosed during the AYA window.

Strikingly, 14% of these YAs had developed a second primary malignancy, underscoring an alarming predisposition for subsequent cancers in this demographic. Furthermore, cardiovascular diseases, particularly hypertension, affected about 60% of these patients, accompanied by frequent neurological, endocrine, and psychological comorbidities. Compounding these risks, lifestyle factors such as overweight and obesity prevailed in over half of the patients, with smoking histories—both former and current—adding to their vulnerability. Screening adherence varied, with breast cancer screening rates at 82%, colon cancer at 60%, and cervical cancer trailing at 40%. Topalian emphasizes the critical role oncology primary care providers must play in delivering comprehensive, lifelong monitoring and tailored preventative care to address the complex interplay of late effects and chronic conditions in this high-risk population.

Moving to hematologic malignancies, a separate investigation led by Eric Vick, MD, PhD, aims to quantify and characterize the overexpression of a protein isoform known as IRAK4L in acute myeloid leukemia (AML). Prior studies had recognized IRAK4L as hyperactive in AML cells, but precise expression levels and implications for chemotherapeutic resistance had remained elusive. By assessing animal models and patient-derived AML cell lines, Vick’s group demonstrated that most AML cancer cells express predominantly the IRAK4L isoform. When treated with azacitidine, a hypomethylating agent, and venetoclax, a targeted BCL-2 inhibitor, transient suppression of IRAK4L expression was observed. However, post-treatment recovery led to restoration of baseline protein levels, indicating that existing therapies only temporarily modulate this pro-tumorigenic pathway.

The implications of these findings extend to the development of next-generation pharmacologic inhibitors targeting IRAK4 as part of multifaceted therapeutic regimens. Vick anticipates that novel IRAK4 inhibitors may enter clinical trials imminently, presenting opportunities to overcome AML’s notorious ability to evade current treatment modalities. This research exemplifies the strategic shift toward precision medicine guided by molecular vulnerabilities inherent to specific leukemic subtypes.

Immunotherapy remains a dynamic frontier in oncology, highlighted by investigation into oncolytic viral therapies. The Phase 2 IGNYTE trial explores RP1, a genetically modified herpes simplex virus type 1 engineered to selectively infect and lyse tumor cells while stimulating systemic antitumor immunity. Under the guidance of Trisha Wise-Draper, MD, PhD, biosafety analyses of RP1’s behavior in patients with skin cancers revealed minimal viral dissemination beyond tumor sites. Detection of viral particles in blood, urine, and patient surfaces was negligible, with no secondary infections reported among close contacts or family members.

These safety data affirm that RP1’s replication remains tumor-restricted, a critical property to mitigate risks of contagion and systemic viral illness. Wise-Draper highlights that such reassuring biosafety profiles are essential for the continued evaluation of oncolytic viruses as viable immunotherapeutic agents. The ongoing trial aims to balance potent oncolytic activity with rigorous safety standards, setting the stage for broader incorporation of engineered viral platforms in oncology.

Another compelling study addresses the therapeutic void in adenoid cystic carcinoma (ACC), a rare, indolent yet treatment-resistant head and neck malignancy. Researchers under the mentorship of Wise-Draper initiated a Phase 2 clinical trial assessing amivantamab, a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and MET pathways. Previously approved for lung cancer-resistant variants, amivantamab was evaluated for its potential to surmount ACC’s notorious drug resistance. Among the 21 enrolled patients, partial tumor responses were noted, with one case achieving a 30% reduction in lesion size. Additionally, 10 patients demonstrated stable disease, culminating in a clinical benefit rate of 61%.

Importantly, the therapeutic regimen was well tolerated, with side effects confined primarily to manageable infusion reactions and skin rashes. Patient-reported quality of life remained stable throughout treatment. Researchers plan to conduct extensive molecular profiling of tumor specimens to identify predictive biomarkers that may refine patient selection and optimize therapeutic efficacy. This work lays the foundation for future amivantamab combination trials or expanded enrollment to validate its role in ACC management.

In a groundbreaking advancement for rare pediatric and young adult kidney cancers, James I. Geller, MD, reports findings from the national Phase 2 AREN1721 trial targeting translocation renal cell carcinoma (tRCC). This aggressive neoplasm is driven by chromosomal rearrangements involving TFE3 or TFEB transcription factors, resulting in aberrant gene expression and unchecked tumor growth. The trial evaluated a novel combination therapy pairing nivolumab, an immune checkpoint inhibitor that invigorates antitumor T-cell responses, with axitinib, a tyrosine kinase inhibitor that disrupts tumor angiogenesis.

Though the study enrolled just 13 patients aged 7 to 42, outcomes were promising. The dual therapy extended median progression-free survival to 10.5 months, markedly outperforming nivolumab monotherapy, which yielded a median progression of 1.8 months. Approximately one-third of combination recipients experienced partial tumor regression, a feat not observed with single-agent immunotherapy. Adverse event profiles were consistent with known drug toxicities and presented no unexpected safety concerns. Geller underscores the significance of these results, signaling a pivotal step toward improved treatment paradigms for tRCC, although he stresses the necessity for continued clinical innovation.

Collectively, these diverse research initiatives highlight the University of Cincinnati Cancer Center’s commitment to advancing oncologic knowledge across age groups, cancer types, and therapeutic modalities. From elucidating the complex long-term health needs of AYA cancer survivors to pioneering molecularly guided treatments in intractable malignancies, the findings presented at ASCO 2025 portend a future in which personalized cancer care is not an aspiration but a standard. As cancer patients live longer and treatments evolve, multidisciplinary endeavors such as these ensure that survivorship and quality of life receive as much attention as disease eradication.

Emerging themes across these studies include the urgent necessity for longitudinal monitoring of high-risk populations, interdisciplinary collaboration bridging basic science and clinical practice, and regulatory frameworks that support innovative trial designs. Moreover, advances in molecular profiling and immune oncology herald an era where therapeutic resistance can be anticipated and circumvented rather than merely managed. These strides bring hope that tomorrow’s cancer treatments will be smarter, more effective, and tailored uniquely to each patient’s biology and experience.

The spotlight on adolescent and young adult oncology exemplifies a critical recalibration in the oncology community’s approach to survivorship. Tailored prevention, comprehensive primary care, and enhanced provider-patient education form the cornerstones of this evolving paradigm. Likewise, efforts to refine immunotherapies and targeted agents shown in trials of IRAK4 inhibitors, oncolytic viruses, and antibody-drug conjugates underscore a nuanced understanding of cancer’s molecular underpinnings and immune evasion tactics.

As the ASCO Annual Meeting convenes, the collective momentum fosters optimism and underscores the vibrancy of cancer research. The University of Cincinnati Cancer Center’s multifaceted contributions, spanning from bench to bedside, reflect the broader shift in oncology toward integration, precision, and compassionate care for all patients, regardless of age, cancer type, or stage.

—

Subject of Research: Oncology research encompassing adolescent and young adult cancer survivorship, acute myeloid leukemia molecular targets, oncolytic virus safety, rare head and neck cancer therapies, and novel treatments for rare kidney cancers.

Article Title: University of Cincinnati Cancer Center Unveils Pioneering Research at ASCO 2025: Advances in AYA Survivorship, AML Molecular Targets, and Novel Cancer Therapies

News Publication Date: May 2025

Web References:
– IGNYTE trial (NCT03767348) – https://clinicaltrials.gov/study/NCT03767348

Keywords: Oncology, Adolescent and Young Adult (AYA) Survivorship, Acute Myeloid Leukemia (AML), IRAK4L Protein, Oncolytic Virus, RP1, Amivantamab, Adenoid Cystic Carcinoma (ACC), Translocation Renal Cell Carcinoma (tRCC), Immunotherapy, Targeted Therapy, Nivolumab, Axitinib

A particularly compelling study delves into the multifaceted role of interleukin-9 (IL-9), a small protein previously known to both exacerbate and inhibit tumor growth, contingent on cancer type. Until now, IL-9’s influence on HNC remained an enigma. The research, led by Sam Nusbaum, reveals that IL-9 expression is notably elevated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) compared to healthy individuals. Intriguingly, higher IL-9 mRNA levels correlated with poor patient survival, underscoring its potential as a prognostic biomarker. At the cellular level, IL-9 appears to induce the secretion of IL-6, a cytokine notorious for impairing the cytolytic function of immune cells tasked with eliminating cancer.

However, the story of IL-9 is far from linear. Experimental animal models demonstrated that increased IL-9 is paradoxically associated with reduced tumor size and weight, hinting at counterbalancing immune responses. This dichotomy suggests that IL-9’s role in tumorigenesis may be context-dependent, influenced by intricate molecular signaling and immune microenvironment dynamics. Nusbaum’s future investigations aim to dissect these pathways in precise molecular detail, shedding light on the dualistic nature of IL-9 in cancer progression and immune regulation.

Complementing this exploration, Lindsey Bachmann investigates signaling pathways integral to the function of natural killer (NK) cells—immune effectors pivotal in identifying and destroying cancer cells. Their research illuminates how blocking the CXCR2 receptor pathway impairs tumor growth in murine models, but only in the presence of NK cells and CD8+ T lymphocytes. CXCR2, a chemokine receptor, is crucial in directing immune cell trafficking and activation within tumors. This finding underscores the therapeutic potential of targeting immune cell receptor signaling to amplify anti-tumor immunity. Ongoing work will elucidate the mechanistic interplay between CXCR2 inhibition and immune effector cell behavior, potentially opening avenues to novel immunotherapies for HNC.

Amid these molecular insights, researchers led by Katelyn Jansen are pioneering efforts to improve noninvasive cancer diagnostics. Traditional tumor biopsies, while the gold standard for evaluating treatment response and disease progression, are often limited by accessibility and patient discomfort. Jansen’s team has standardized protocols for isolating peripheral blood mononuclear cells (PBMCs) from patient blood samples, demonstrating that delayed processing up to 24 hours does not compromise cell viability. This methodological advancement could revolutionize how clinicians monitor immunotherapy responses, allowing for safer, more frequent, and widely accessible assessments. The team plans to validate their findings across multiple institutions and compare PBMC-based analyses with conventional biopsy data to confirm efficacy.

Beyond diagnostics, Jansen also probed the synergistic potential of combining immunotherapy with radiation modalities in recurrent HNC. Specifically, she investigated the effects of proton therapy (PT) versus conventional X-ray radiation therapy (XRT) when paired with immune checkpoint inhibitors like anti-PD1 antibodies. Both PT and XRT effectively stymied tumor growth in vivo and increased immune cell infiltration, yet the addition of immunotherapy conferred only modest additional benefits. These preliminary data suggest that while radiation primes the tumor microenvironment for immune infiltration, the anticipated synergism with immunotherapy remains elusive in animal models. Future experimental designs will aim to optimize these combinatorial strategies, potentially by refining dosing schedules or leveraging novel immune modulators.

Turning to breast cancer, the University of Cincinnati team explored the impact of nonmuscle myosin IIA (NMIIA) within HER2-positive tumors—aggressive breast cancers marked by elevated HER2 protein levels driving rapid proliferation and metastasis. Through molecular interrogation, the team identified NMIIA’s interaction with HER3, a related receptor, modulating intracellular signaling pathways that contribute to drug resistance and metastatic behavior. Clinical correlations revealed that elevated NMIIA expression, particularly in lymphovascular invasion (LVI)-positive tumors, portends worse patient survival. This discovery positions NMIIA as a potential therapeutic target, and the lab is actively developing a novel NMIIA inhibitor. If successful, this approach could augment current HER2-targeted therapies, combating resistance and metastatic spread.

In an altogether different pathological context, lymphangioleiomyomatosis (LAM)—a rare lung disease characterized by cystic lung remodeling due to aberrant smooth muscle-like cell proliferation—has been the focus of cutting-edge metabolic research. First author Evans Abor examined the enzyme PHGDH and its regulatory nexus with mTORC1, a signaling hub known to drive LAM progression. Remarkably, PHGDH expression was markedly increased in diseased tissues. Pharmacological inhibition of PHGDH not only induced apoptosis in LAM cells but also impaired key metabolic processes such as mitochondrial function and macromolecular biosynthesis, which are essential for tumor cell viability. Notably, combinatorial treatment with rapamycin, an established mTORC1 inhibitor, potentiated autophagy—a cellular clearance mechanism—highlighting a promising therapeutic synergy. This metabolic angle opens vast potential for overcoming therapeutic resistance and curbing disease progression.

The Cancer Center’s portfolio of research presented at AACR 2025 also includes advanced studies in colorectal cancer, where co-targeting HER family receptors and mutant KRAS mutations has shown efficacy, and investigations into the role of Stat1 in tumor immunity within tuberin-deficient cells, a finding with implications for LAM pathology. These multifaceted efforts underscore the Center’s broad commitment to deciphering the complex molecular and immunological landscapes that define cancers and rare diseases.

Collectively, these studies highlight the burgeoning era of precision oncology, wherein deep molecular insights are translated into targeted, patient-centric interventions. The convergence of immunology, molecular biology, and translational medicine embodied in this research holds transformative promise: personalized treatments informed by tumor and immune profiling, minimally invasive diagnostics, and combination therapies that outmaneuver tumor resistance mechanisms.

As the AACR Annual Meeting approaches, the University of Cincinnati Cancer Center’s contributions stand poised to ignite new conversations and collaborations, catalyzing advancements that may soon reshape clinical cancer care. The synthesis of fundamental discovery and applied research presented by these emerging scientists and established investigators exemplifies the dynamic pursuit of innovative solutions to some of oncology’s most pressing challenges.

Subject of Research: Head and neck cancer, breast cancer, lymphangioleiomyomatosis, cancer immunotherapy, metabolic vulnerabilities in rare diseases.

Article Title: University of Cincinnati Cancer Center Unveils Novel Insights at AACR 2025: IL-9’s Paradoxical Role, Immune Signaling Pathways, and Emerging Therapeutic Targets

News Publication Date: Information not provided.

Web References: Information not provided.

References: Information not provided.

Image Credits: Information not provided.

Keywords: Head and neck cancer, breast cancer, tumor growth, cancer immunotherapy, inhibitory effects, animal models, peripheral blood mononuclear cells, radiation therapy, NK cell receptor signaling, cell responses, cancer research.